Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;13(1):77-85.
doi: 10.6004/jadpro.2022.13.1.7. Epub 2022 Feb 1.

Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Emily Behren Ketchum  1 , Andrea Clarke  1 , Amber B Clemmons  1
Affiliations

Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Emily Behren Ketchum et al. J Adv Pract Oncol. 2022 Jan.

Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by proliferation of plasma cells with or without production of monoclonal immunoglobulins. Management of patients with MM begins with induction therapy, typically a proteasome inhibitor (PI) with dexamethasone and an immunomodulator (IMID), followed by autologous hematopoietic stem cell transplantation in eligible patients. Although various treatments are available, MM is considered incurable, and patients with progression after multiple treatment lines, including CD38 monoclonal antibodies, have a median overall survival of 8.6 months. Belantamab mafodotin-blmf (Blenrep) is a first-in-class antibody-drug conjugate directed against B-cell maturation antigen (BCMA) that obtained U.S. Food and Drug Administration accelerated approval in August 2020 for patients with multiply relapsed/refractory MM. This article provides information on the mechanism of action, efficacy, safety, monitoring, and current place in therapy for belantamab mafodotin-blmf.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. Abramson, H. N. (2020). B-Cell Maturation Antigen (BCMA) as a target for new drug development in relapsed and/or refractory multiple myeloma. International Journal of Molecular Sciences, 21(15), 5192. 10.3390/ijms21155192 - DOI - PMC - PubMed
    1. American Society of Clinical Oncology. (2021a). Multiple Myeloma: Statistics. https://www.cancer.net/cancer-types/multiple-myeloma/statistics
    1. American Society of Clinical Oncology. (2021b). Multiple Myeloma: Types of Treatment. https://www.cancer.net/cancer-types/multiple-myeloma/types-treatment
    1. Atrash, S., Bhutani, M., Paul, B., Voorhees, P. M., & Usmani, S. Z. (2020). Management of newly diagnosed transplant ineligible multiple myeloma. Leukemia & Lymphoma, 61(11), 2549–2560. 10.1080/10428194.2020.1786558 - DOI - PubMed
    1. Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D.,…Banerjee, A. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. The Lancet, 398(10297), 314–324. 10.1016/s0140-6736(21)00933-8 - DOI - PubMed

LinkOut - more resources